why choose us

300×250 Ad Slot

Research Article: Precision treatment of chalazion based on AI-driven risk stratification: a prospective study of triamcinolone acetonide combined with intense pulsed light therapy

Date Published: 2026-06-15

Abstract:
To evaluate the rates of chalazion recurrence following intralesional triamcinolone acetonide (TA), intense pulsed light (IPL), or combined TA?+?IPL therapy and to validate an AI-enhanced risk stratification strategy. This prospective, observational study enrolled 366 patients. To eliminate immortal time bias and circular reasoning, LASSO-Cox regression with 10-fold cross-validation was employed to identify purely baseline predictors: age, Demodex infection, chronicity, and meibomian gland dysfunction (MGD). These baseline predictors were integrated into a clinical Cox proportional hazards model and a survival-based XGBoost model, which were subsequently merged into a hybrid framework. Performance was assessed via time-dependent area under the curve (AUC), net reclassification improvement (NRI), Kaplan–Meier analysis, and decision curve analysis (DCA). The 3-month complete resolution rate was significantly higher in the combined TA?+?IPL group (95.2%) compared to the TA-only (90.8%) and IPL-only (79.4%) groups ( p <?0.001). During follow-up, 60 recurrence events (16.4%) occurred. Recurrence rates differed significantly (? 2 =?31.73, p <?0.001) as follows: IPL group (38.2%), TA group (15.4%), and TA?+?IPL group (8.3%). Multivariate Cox analysis revealed that demodex infection, age, chronicity, and MGD were independent risk factors for chalazion recurrence. The hybrid model achieved an AUC of 0.822, outperforming the clinical (0.745) and XGBoost (0.821) ( p <?0.05) models. AI integration significantly refined the risk estimates (NRI?=?0.365, p =?<?0.001). In the high-risk subgroup, recurrence rates reached 83.3–91.7% with monotherapy, whereas combined TA?+?IPL therapy significantly reduced the recurrence rate to 60.0%. DCA confirmed that the hybrid model consistently yielded the greatest net clinical benefit. A hybrid AI-clinical model significantly improved the prediction of chalazion recurrence. Combined TA?+?IPL therapy demonstrated superior efficacy, particularly for high-risk patients. This framework provides a robust decision-support tool for precision management and the systematic reduction of chalazion recurrence.

Introduction:
Chalazion represents a localized granulomatous inflammatory response triggered by the obstruction of meibomian gland ducts, which leads to lipid retention and subsequent extravasation into the tarsal collagenous stroma ( 1 , 2 ). Although chalazion is frequently classified as a benign and self-limiting condition, it remains among the most prevalent eyelid disorders in clinical practice, often causing considerable ocular discomfort, visual disturbances, esthetic concerns, and a substantial psychological burden in…

Read more

300×250 Ad Slot